ITREN expanded its International cooperation with Monos Group, Mongolia in April, 2018.
Institute recently visited to Monos Group in Mongolia. The Group involved Drug development Institute, Pharmaceutical University and GMP standard Factory for manufacturing drugs.
The joint researchers will focus on Osteoporosis drug development and Allergy targeted drug delivery.
ITREN expanded its International cooperation with Peking University Shenzhen Graduate School in Dec, 2017.
ITREN has recently started collaborative works with Pf. hou Qiang and Li Shu-peng about utilization of therapeutic nanoparticles for treating neuronal diseases. Impactful research will be expected from these collaborative works.
ITREN expanded its International cooperation with School of Medicine, Yanbian University in July, 2015.
Institute has recently signed Memorandum of Understanding Agreement with School of Medicine, Yanbian University for joint research in tissue engineering and translational work.
Yanbian University has been selected as one of the Top Universities in China and supported by the State “211Project”.
The joint researches will focus on repairing mandibular defect by use of particles and stimulating cartilage regeneration through cartilage cells and synthetic polymer scaffold.
Prof. Kim HW granted NRF fund (300M won ~300,000$) per year up to 5 years for the research on immune- or angio-modulatory biomaterials.
A new type of cement (named 'nanocement') formulated with bioactive glass nanoparticles showed potential performance including angiogenic stimulation and osteoinductivity. The work was published in Biomaterials, 2018, 162, 183, by Kang MS et al.
A collaborative commercialization research institute, named GENTREN (GENoss + itREN) established with the supportive fund (500M/y up to 2 years) from NRF.
Gentren started to develop and commercialize dental synthetic bone graft materials and other root canal filling materials.
Our research and technologies initiated to become reality to the market throughout this project.
This was motivated by the transfer of two intellectural properties of Prof. Kim HW to biomaterials company (Genoss) with 100M won and 3% royalty